Skip to main content
Ab&B Bio-Tech CO., LTD. JS logo

Ab&B Bio-Tech CO., LTD. JS — Investor Relations & Filings

Ticker · 2627 ISIN · CNE1000071P9 HKEX Manufacturing
Open in API
Filings indexed 63 across all filing types
Latest filing 2026-05-27 Governance Information
Country HK Hong Kong
Listing HKEX 2627

About Ab&B Bio-Tech CO., LTD. JS

http://www.abbbio.com

Ab&B Bio-Tech CO., LTD. JS is a biopharmaceutical company engaged in the research, development, manufacturing, and commercialization of human vaccines and biological preparations that confer active immunity. The company's mission centers on developing globally innovative vaccines and utilizing new technologies to improve traditional vaccines. Its comprehensive pipeline targets infectious diseases and includes candidates across viral, bacterial, conjugate, subunit, and mRNA platforms. The primary commercial product is the Quadrivalent Subunit Influenza Vaccine, approved for individuals aged six months and above. Advanced pipeline assets, such as the 23-valent Pneumococcal Polysaccharide Vaccine and the Freeze-dried Human Rabies Vaccine (Human Diploid Cell), have completed Phase I clinical trials. R&D operations are supported by facilities in Shanghai and Taizhou, with the company emphasizing scientific validation through publications in international journals.

Recent filings

Filing Released Lang Actions
LIST OF DIRECTORS AND THEIR ROLES AND FUNCTIONS
Governance Information Classification · 75% confidence The document is a formal listing of the company’s board composition and committee memberships, detailing the roles and functions of executive, non-executive and independent directors and their committee assignments. It does not present financial data or announce a transaction, dividend, or earnings, nor does it appear to merely publish a report that is attached elsewhere. Instead, it outlines the board structure and governance framework of the company, which aligns with the definition of Governance Information (CGR).
2026-05-27 English
ARTICLES OF ASSOCIATION
Governance Information Classification · 89% confidence The document is the company's Articles of Association outlining corporate governance provisions (general provisions, share issuance, board of directors, senior management, audit, notices, amendments, etc.). It serves as the internal constitution and governance framework rather than a financial report or announcement. This matches the definition of Governance Information (CGR).
2026-05-27 English
(1) POLL RESULTS OF THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026 (2) ABOLITION OF THE SUPERVISORY COMMITTEE, AMENDMENTS TO THE ARTICLES OF ASSOCIATION AND RELATED INTERNAL CORPORATE GOVERNANCE POLI
Declaration of Voting Results & Voting Rights Announcements Classification · 90% confidence The document is an announcement by a Hong Kong-listed company detailing the poll results of its Extraordinary General Meeting (EGM), including vote counts for special and ordinary resolutions, and the outcomes of shareholder votes (abolition of the supervisory committee, amendments to articles, director appointments, auditor appointment). This matches the definition of Declaration of Voting Results & Voting Rights Announcements (code DVA).
2026-05-27 English
VOLUNTARY ANNOUNCEMENT - COMMENCEMENT OF PHASE I AND PHASE II CLINICAL TRIALS FOR RECOMBINANT RSV VACCINE (CHO CELL) (ADJUVANT)
Regulatory Filings Classification · 60% confidence The document is a voluntary announcement by Ab&B Bio-Tech regarding the commencement of Phase I and Phase II clinical trials for a vaccine. It contains no financial data, no management changes, no voting results, no capital transactions, no legal proceedings or M&A activity. It is a corporate update required under listing rules but does not fit any specialized category (e.g., earnings, interim report, board changes). Therefore it defaults to the general regulatory/announcement category: RNS.
2026-05-13 English
VOLUNTARY ANNOUNCEMENT - IND APPROVAL BY CHINA CDE FOR MRNA RSV VACCINE
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by Ab&B Bio-Tech regarding the approval of an Investigational New Drug (IND) application for their mRNA RSV vaccine by the China Center for Drug Evaluation (CDE). It includes background information about the company and the vaccine, and also mentions the continued suspension of trading of the company's shares on the Hong Kong Stock Exchange. The document is relatively short (3919 characters) and serves as a business update and regulatory announcement rather than a financial report or detailed filing. It does not contain financial statements, audit information, or detailed management discussion. It is not an earnings release, annual report, or interim report. It is also not a regulatory certification or officer attestation. The content fits best with a Regulatory Filing (RNS) as it is a general regulatory announcement informing shareholders and investors about a material business development and trading suspension, without fitting into more specific categories like capital update, management change, or legal proceedings.
2026-05-08 English
FORM OF PROXY FOR THE FIRST EXTRAORDINARY GENERAL MEETING OF 2026 TO BE HELD ON WEDNESDAY, MAY 27, 2026 AND ANY ADJOURNMENT THEREOF
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Form of Proxy for an Extraordinary General Meeting (EGM) scheduled for May 27, 2026. It includes instructions for shareholders to appoint proxies to vote on resolutions such as abolition of the supervisory committee, amendments to articles of association, appointment of directors, and appointment of auditors. The document is procedural and related to shareholder voting at a general meeting. It is not a report of voting results, nor is it a report of financial performance or management discussion. It is a solicitation document for proxy voting at a shareholder meeting. Therefore, it fits the category of Proxy Solicitation & Information Statement (PSI). The document length (7527 characters) and content confirm it is not a brief announcement or a report publication notice but a full proxy form with detailed instructions and notes.
2026-05-08 English

Browse filings by year

2 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.